BCIQ Profiles

Company Profile ReportTarget Profile Report
0826 Neurogastrx series B
BioCentury & Getty Images

Finance

Neurogastrx: $60M crossover round to advance de-risked GI assets

Emerging Company Profile: Funding, assist from Vivo to land Phase III-ready Daewoong asset readies biotech to build on its CEO’s Ironwood roots

Fresh funding and an assist from lead investor Vivo to bring in a Phase III-ready Daewoong asset sets Neurogastrx up to capitalize on its CEO’s Ironwood roots.

Aug 26, 2021 | 10:58 PM GMT

A June deal that came together through Vivo Capital brought a Phase III-ready asset into the hands of

Read the full 874 word article

How to gain access

Continue reading with a
two-week free trial.